A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...

Recent developments, however, suggest that strategies to treat pain are starting to match its complexity with a new sophistication. The management of chronic pain in general is now being broadly ...

Other research has shown red light therapy could minimize the appearance of wrinkles, hyperpigmentation, and broken blood ...

The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...

People undergoing hemodialysis treatment for kidney failure often experience chronic pain related to their condition, but it ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

Future large-scale prospective studies are needed to confirm the clinical value of using genetic information to guide pain management therapy. The Mayo Clinic (MN, USA) is routinely offering ...

If you’re in pain and you’re looking for relief in the form of an over-the-counter drug, you’ve got a slew of options.

In conclusion, the study demonstrates the potential of brain biomarkers like CME and PAF to revolutionize pain management. By ...